Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia
Background: We aim to analyze the efficacy and safety of Venetoclax (Ven) added to cladribine + cytarabine + granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG ± Ida/Mito) regimen as a salvage treatment of relapsed/refractory acute myeloid leukemia (RR-AML). Methods: A...
Saved in:
Main Authors: | Yu Zhang, Zhao Yin, Zurong Yao, Dan Xu, Xuejie Jiang, Xiaqi Nie, Dandan Chen, Hongsheng Zhou, Pengcheng Shi, Hui Liu, Qifa Liu, Guopan Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/20406207251319603 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Isolated central nervous system relapse in blast crisis of chronic myeloid leukemia: a case report
by: Hari Priya Raghvan, et al.
Published: (2025-01-01) -
Bone marrow immune cells and drug resistance in acute myeloid leukemia
by: Miao Zhang, et al.
Published: (2025-02-01) -
Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
by: Melea A. Ward, et al.
Published: (2015-04-01) -
Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
by: Ishan Hirji, et al.
Published: (2014-09-01) -
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
by: Zoe King, et al.
Published: (2025-03-01)